Ashland Inc. Posts Q3 Results

Ashland Inc. (NYSE: ASH), a leading global additives and specialty ingredients company, has released its financial results for the third quarter of fiscal 2024, ending June 30. The company reported sales of $544 million, nearly flat compared to $546 million in the same quarter last year. Despite increased sales volumes in the Personal Care and Specialty Additives segments, lower Life Sciences volumes and unfavorable foreign currency fluctuations affected overall performance. Notably, Ashland's ongoing portfolio optimization in the carboxymethylcellulose (CMC) and methylcellulose (MC) sectors led to a $15 million reduction in sales, as anticipated.

Financial Overview

The company’s net income for the quarter was $6 million, a sharp decline from $50 million in the prior-year quarter. Income from continuing operations fell to $31 million, or $0.60 per diluted share, from $42 million, or $0.79 per diluted share, a year earlier. However, adjusted income from continuing operations, excluding intangible amortization expenses, rose to $75 million, or $1.49 per diluted share, up from $65 million, or $1.23 per share, in the previous year. Ashland's adjusted EBITDA also saw a 5% increase to $139 million, driven by higher sales and production volumes, a favorable product mix, and deflationary raw material costs, partially offset by unfavorable pricing and increased selling, administrative, research, and development (SARD) expenses.

Cash flow from operating activities totaled $128 million, down slightly from $137 million in the prior-year quarter, while ongoing free cash flow improved to $112 million from $97 million. The company also repurchased 1.3 million shares during the quarter, leaving $770 million under its existing share repurchase authorization.

Segment Performance

• Life Sciences: Sales dropped 11% to $195 million, mainly due to weaker demand in the vinyl pyrrolidone and derivatives (VP&D) segment for pharmaceutical and crop-care markets. Adjusted EBITDA decreased to $59 million from $72 million.
• Personal Care: Sales increased by 20% to $175 million, driven by higher volumes in skin and hair care products. Adjusted EBITDA improved significantly to $51 million from $35 million in the prior-year quarter.
• Specialty Additives: Sales remained relatively stable at $150 million, with higher volumes offset by lower pricing, particularly in Asia. Adjusted EBITDA rose to $38 million from $29 million.
• Intermediates: Sales fell by 16% to $36 million, primarily due to lower pricing in merchant sales and captive internal butanediol (BDO) sales. Adjusted EBITDA dropped to $9 million from $16 million.

Outlook for Q4 and Full Fiscal Year 2024

Ashland has issued a cautious outlook for the fourth quarter, expecting sales between $530 million and $540 million, and adjusted EBITDA between $130 million and $140 million. For the full fiscal year 2024, the company projects sales of approximately $2.1 billion and adjusted EBITDA in the range of $465 million to $475 million. CEO Guillermo Novo emphasized the company's strategic focus on disciplined operations, portfolio optimization, and long-term growth initiatives despite a challenging market environment. Novo acknowledged the "choppy demand environment" but expressed confidence in Ashland's ability to navigate these challenges and capitalize on future growth opportunities.

Highlights:

• Ashland Inc. reported Q3 2024 sales of $544 million, nearly unchanged from the prior-year quarter.
• Net income decreased significantly to $6 million, down from $50 million in Q3 2023.
• Adjusted EBITDA increased by 5% to $139 million, driven by higher sales volumes and favorable product mix.
• The company repurchased 1.3 million shares during the quarter, with $770 million remaining under the repurchase authorization.
• Ashland expects Q4 sales between $530 million and $540 million and full-year sales of approximately $2.1 billion.

Date Source: https://investor.ashland.com/news-releases/news-release-details/ashland-reports-financial-results1-third-quarter-fiscal-2024